News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
276,331 Results
Type
Article (14556)
Company Profile (107)
Press Release (261660)
Multimedia
Podcasts (67)
Webinars (13)
Section
Business (88919)
Career Advice (477)
Deals (15580)
Drug Delivery (75)
Drug Development (36974)
Employer Resources (51)
FDA (6430)
Job Trends (6329)
News (151837)
Policy (14236)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (451)
Accelerated approval (13)
Adcomms (10)
Allergies (67)
Alliances (23450)
ALS (57)
Alzheimer's disease (490)
Antibody-drug conjugate (ADC) (101)
Approvals (6616)
Artificial intelligence (202)
Autoimmune disease (43)
Automation (12)
Bankruptcy (155)
Best Places to Work (4424)
BIOSECURE Act (9)
Biosimilars (119)
Biotechnology (42)
Bladder cancer (39)
Brain cancer (30)
Breast cancer (171)
Cancer (1337)
Cardiovascular disease (153)
Career advice (429)
Career pathing (13)
CAR-T (52)
CDC (9)
Cell therapy (155)
Cervical cancer (9)
Clinical research (32203)
Collaboration (731)
Compensation (325)
Complete response letters (33)
COVID-19 (800)
CRISPR (43)
C-suite (435)
Cystic fibrosis (59)
Data (1835)
Denatured (18)
Depression (45)
Diabetes (133)
Diagnostics (1408)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (15)
Drug discovery (115)
Drug pricing (119)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33632)
Editorial (22)
Employer branding (4)
Employer resources (46)
Events (39306)
Executive appointments (528)
FDA (7533)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (439)
Gene editing (70)
Generative AI (18)
Gene therapy (167)
GLP-1 (456)
Government (1425)
Grass and pollen (4)
Guidances (164)
Healthcare (3670)
HIV (11)
Huntington's disease (10)
IgA nephropathy (37)
Immunology and inflammation (70)
Immuno-oncology (14)
Indications (53)
Infectious disease (866)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (114)
Interviews (62)
IPO (5985)
IRA (35)
Job creations (2098)
Job search strategy (384)
JPM (29)
Kidney cancer (9)
Labor market (28)
Layoffs (207)
Leadership (8)
Legal (3482)
Liver cancer (22)
Longevity (8)
Lung cancer (185)
Lymphoma (124)
Machine learning (13)
Management (17)
Manufacturing (418)
MASH (67)
Medical device (1352)
Medtech (1359)
Mergers & acquisitions (10023)
Metabolic disorders (455)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (87)
Neuropsychiatric disorders (38)
Neuroscience (904)
Neurotech (1)
NextGen: Class of 2026 (1639)
Non-profit (630)
Now hiring (17)
Obesity (244)
Opinion (143)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (81)
Partnered (12)
Patents (222)
Patient recruitment (116)
Peanut (12)
People (29963)
Pharmaceutical (64)
Pharmacy benefit managers (19)
Phase 1 (8367)
Phase 2 (13592)
Phase 3 (12291)
Pipeline (1928)
Policy (142)
Postmarket research (1403)
Preclinical (3362)
Press Release (25)
Prostate cancer (85)
Psychedelics (17)
Radiopharmaceuticals (136)
Rare diseases (353)
Real estate (2725)
Recruiting (18)
Regulatory (11026)
Reports (15)
Research institute (589)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (84)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (82)
Sponsored (10)
Startups (1670)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (47)
Vaccines (241)
Venture capital (34)
Weight loss (152)
Women's health (27)
Worklife (4)
Date
Last 7 days (178)
Last 30 days (682)
Last 365 days (10494)
2026 (960)
2025 (10805)
2024 (12628)
2023 (14386)
2022 (19803)
2021 (20376)
2020 (19296)
2019 (15116)
2018 (11859)
2017 (13985)
2016 (13251)
2015 (15576)
2014 (12518)
2013 (10654)
2012 (11462)
2011 (11994)
2010 (10934)
Location
Africa (320)
Alabama (19)
Alaska (1)
Arizona (80)
Arkansas (3)
Asia (21002)
Australia (2706)
California (3199)
Canada (1486)
China (555)
Colorado (143)
Connecticut (130)
Delaware (123)
Europe (41043)
Florida (602)
Georgia (64)
Hawaii (1)
Idaho (10)
Illinois (350)
India (44)
Indiana (243)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (3)
Maryland (426)
Massachusetts (2597)
Michigan (49)
Minnesota (168)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1400)
New Mexico (7)
New York (910)
North Carolina (625)
North Dakota (2)
Northern California (1461)
Ohio (81)
Oklahoma (5)
Oregon (18)
Pennsylvania (719)
Puerto Rico (12)
Rhode Island (18)
South America (511)
South Carolina (10)
Southern California (1393)
Tennessee (55)
Texas (460)
United States (12783)
Utah (60)
Virginia (162)
Washington D.C. (45)
Washington State (248)
West Virginia (1)
Wisconsin (38)
Wyoming (2)
276,331 Results for "slate pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Medical Care Technologies (OTC Pink:MDCE) Enters Final Phase of Testing for First Consumer App, With Beta Launch Slated for Q4 2025
November 7, 2025
·
1 min read
Clinical research
5 Clinical Readouts to Watch in H1 2026
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer’s drug—are poised to reshape therapeutic landscapes.
January 5, 2026
·
7 min read
·
Ben Hargreaves
Neuroscience
Praxis Ends Epilepsy Study Early Due to Strong Results, Heads to FDA
Praxis Precision Medicines has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, for which an approval application is slated for early 2026.
December 5, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly Continues Manufacturing Push With $1.2B Puerto Rico Facility for GLP-1 Pill
The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of around 1,000 construction-related roles.
October 30, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
February 7, 2025
·
10 min read
Drug Development
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that a paper detailing the development of its “off-the-shelf” neoantigen platform, SLATE, recently published in Nature Medicine.
April 15, 2024
·
7 min read
Business
Envoy Medical Announces Proposed Board Slate of Experienced Medical Device and Financial Leaders
Envoy Medical® Corporation (“Envoy”), a hearing health company, today announced the proposed slate of seven directors to be voted on during the special meeting of stockholders to be held by its merger partner
September 19, 2023
·
15 min read
Business
Maryland Tech Council Welcomes New Chair and Slate of Industry Leaders to its Board of Directors
The Maryland Tech Council, the largest technology and life sciences trade association in the state, welcomed a new chair and slate of technology and life sciences leaders to its board of directors.
July 11, 2023
·
3 min read
Genetown
Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
Apnimed, Inc. announced a series of five data presentations and a dinner symposium at the SLEEP 2024 annual meeting.
May 23, 2024
·
8 min read
Earnings
Vertex Tops Q3 Forecast on Strength of Cystic Fibrosis Sales, Raises Full-Year Revenue Guidance
Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid therapy suzetrigine in pain—both slated for January 2025.
November 5, 2024
·
2 min read
·
Tristan Manalac
1 of 27,634
Next
